Major Study Links Common Hospital Antibiotic Cefepime to Increased Mortality Risk in Adults

A widely prescribed antibiotic commonly utilized in hospital settings has been linked to a heightened risk of death among adult patients, according to findings from a comprehensive global investigation. The medication, known as cefepime, is frequently administered to treat an array of severe and potentially life-threatening bacterial infections.

Cefepime belongs to the beta-lactam class of antimicrobial medications, specifically within the cephalosporin subgroup. It is routinely administered through injections or intravenous infusions by healthcare professionals in clinical environments to treat conditions such as pneumonia, urinary tract infections, and complex skin infections.

Beyond standard ailments, the broad-spectrum antibiotic is also deployed against severe, systemic bacterial conditions and central nervous system infections such as meningitis. Additionally, it is a staple treatment for patients experiencing febrile neutropenia, a dangerous medical emergency characterized by high fever paired with a critical shortage of infection-fighting white blood cells.

The newly published study, which appeared in the medical journal JAMA Network Open, evaluated data from 110 randomized clinical trials. In total, the massive research effort reviewed outcomes for more than 22,000 adult and pediatric patients who were administered either cefepime or an alternative beta-lactam antibiotic.

In standard hospital practice, alternative beta-lactam therapies often include various forms of penicillins as well as alternative cephalosporin formulations. Clinicians frequently choose among these related agents based on the suspected pathogen, the severity of the infection, and patient-specific characteristics.

When reviewing patient outcomes across all 110 trials, investigators tracked all-cause mortality occurring within approximately 30 days of receiving treatment. Among the 11,726 patients who were treated with cefepime, 778 deaths were documented, representing an overall mortality rate of 6.6 percent.

By comparison, patients who received alternative beta-lactam treatments experienced a lower mortality rate of 6.2 percent. While this numerical difference may appear modest on the surface, statistical modeling revealed a substantial and consistent trend toward increased risk associated with cefepime use.

Using advanced Bayesian meta-analysis techniques, the researchers calculated a 94.4 percent statistical probability that cefepime was linked to higher all-cause mortality when compared directly against other beta-lactam alternatives.

The statistical association grew even more pronounced when the researchers restricted their evaluation exclusively to high-quality data. In a secondary analysis limited to 73 peer-reviewed published clinical trials, the probability that cefepime carried a higher risk of death climbed to 98.6 percent.

The study further identified notable variations in risk among distinct patient demographics and clinical presentations. The elevated risk of mortality was significantly more evident in adult populations than in pediatric patients, suggesting potential differences in drug clearance and physiological vulnerability.

Furthermore, the heightened mortality correlation was especially pronounced among individuals undergoing treatment for febrile neutropenia. Because these patients are already immunocompromised and critically ill, small differences in medication safety profiles and efficacy can have an outsized impact on clinical outcomes.

While the study established a clear statistical link, researchers noted that pinpointing an exact underlying cause for the excess deaths remains complex. However, documented side effects and pharmacokinetic challenges associated with the drug offer plausible explanations for the observed trends.

According to clinical guidance from the Mayo Clinic, severe adverse reactions associated with cefepime can include serious neurological symptoms such as confusion, diminished consciousness, and seizures. These complications are particularly prevalent among elderly patients and individuals suffering from preexisting renal impairment or kidney disease.

The study authors highlighted that managing cefepime presents a delicate dosing challenge for clinicians. If administered at doses that are too low, the drug fails to reach therapeutic thresholds necessary to eradicate aggressive bacterial infections, leaving patients vulnerable to treatment failure.

Conversely, administering higher doses to maximize bacterial clearance increases the concentration of the drug in the body, significantly elevating the risk of neurotoxicity and other dangerous toxic side effects. This narrow therapeutic window suggests that improper dosage optimization may play a substantial role in patient mortality.

Despite these concerning findings, the study authors emphasized that they do not advise healthcare systems or physicians to discontinue the use of cefepime entirely. The drug remains an indispensable, broad-spectrum therapeutic weapon against a wide variety of multidrug-resistant and severe bacterial pathogens in hospital environments.

Instead of abandoning the antibiotic, the researchers called for urgent updates to clinical guidance, more precise dosage monitoring strategies, and targeted clinical trials. By refining how cefepime is dosed and administered, medical teams can better mitigate toxicities and protect vulnerable hospitalized patients.